West Pharmaceutical Services (WST) 10-K Summaries & Annual Filing History
Review West Pharmaceutical Services, Inc. (WST) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
The filing provides financial metrics and revenue trends for the period, but does not include detailed narrative sections beyond table-of-contents references. The company's reported revenue rose year-over-year, while operating income, net income, and operating cash flow are stated.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$3.1B
Revenue reported for the fiscal year.
Operating income
$584.9M
Income from operations reported for the year.
Net income
$493.7M
Net income reported for the year.
Operating cash flow
$754.8M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $2.9B | +2.0% |
| Dec 31, 2023 | $2.9B | +2.2% |
| Dec 31, 2024 | $2.9B | -1.9% |
| Dec 31, 2025 | $3.1B | +6.3% |
Business overview
The filing references a business description in Item 1, but the supplied text does not contain the actual description. The company is identified as West Pharmaceutical Services, Inc., and the context suggests it operates within the pharmaceutical services industry.
Financial performance
Revenue for the period reached the stated amount, an increase from the prior year, reversing a slight decline in the previous period. Operating income and net income are reported, and operating cash flow exceeded net income. The trend shows revenue growth over the most recent year.
Material risks
The filing references risk factors in Item 1A, but the supplied text does not include any specific risk descriptions. No material risks are detailed in the provided context.
Liquidity and capital
Liquidity and capital resources are discussed in Part II of the filing, but the supplied text does not provide specifics. The company's operating cash flow is reported, indicating internal cash generation.
What to watch
Monitor whether the revenue growth trend continues in the next filing, given the recent reversal from a decline.